Show simple item record

dc.contributor.authorKhabbazi, A
dc.contributor.authorKolahi, S
dc.contributor.authorDastgiri, S
dc.contributor.authorHajialiloo, M
dc.contributor.authorNazeri, M
dc.contributor.authorNazeri, L
dc.contributor.authorSheikholeslami Salmasi, A
dc.contributor.authorGader, S
dc.contributor.authorBak Mohammad Zadeh, S
dc.contributor.authorGhasemi, A
dc.contributor.authorPoormohammad, A
dc.date.accessioned2018-08-26T06:04:52Z
dc.date.available2018-08-26T06:04:52Z
dc.date.issued2014
dc.identifier10.1111/1756-185X.12416
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/41596
dc.description.abstractConsideration of the safety of liver transaminases monitoring every 12آ weeks in patients with inflammatory connective tissue disorders who are treated with methotrexate (MTX).In a retrospective study, the data from rheumatic patients receiving MTX were analyzed. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured every 12آ weeks. Based on the physician's final decision about the continuation of MTX, the patients were classified into one of the following groups: continuation of MTX without MTX dose reduction, MTX dose reduction, MTX discontinuation due to liver complication and MTX discontinuation due to other reasons.A total of 809 patients who were on MTX were included in the study. The mean follow-up duration and the mean duration of treatment with MTX were 31.22 and 19.76آ months, respectively. The mean accumulation dose of MTX was 865.85آ mg. Due to the increase in the level of transaminases in 3.2% of the patients, MTX dose was reduced; and in 1.1% of the cases it was temporarily discontinued. In the follow-up of the patients with elevated transaminases, they returned to normal limits in 99.5% of patients; and only in four cases (0.5%) they remained elevated and MTX was discontinued. The probability of the patients remaining on MTX for 5آ years without discontinuation for liver complications was 98.5%Liver transaminase monitoring every 12آ weeks for MTX-treated patients is safe.
dc.language.isoEnglish
dc.relation.ispartofInternational journal of rheumatic diseases
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectAlanine Transaminase
dc.subjectAntirheumatic Agents
dc.subjectAspartate Aminotransferases
dc.subjectBiomarkers
dc.subjectChemical and Drug Induced Liver Injury
dc.subjectChild
dc.subjectChild, Preschool
dc.subjectClinical Enzyme Tests
dc.subjectDrug Monitoring
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectMethotrexate
dc.subjectMiddle Aged
dc.subjectPatient Safety
dc.subjectPredictive Value of Tests
dc.subjectRetrospective Studies
dc.subjectRheumatic Diseases
dc.subjectRisk Factors
dc.subjectTime Factors
dc.subjectTreatment Outcome
dc.subjectYoung Adult
dc.titleSafety of less frequent monitoring of liver transaminases levels in rheumatic patients treated with low-dose methotrexate.
dc.typearticle
dc.citation.volume17
dc.citation.issue6
dc.citation.spage646
dc.citation.epage52
dc.citation.indexPubmed
dc.identifier.DOIhttps://doi.org/10.1111/1756-185X.12416


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record